WPI 2287 (Propafenone hydrochloride extended-release 425 mg)

Pill imprint WPI 2287 has been identified as Propafenone hydrochloride extended-release 425 mg.

Propafenone is used in the treatment of atrial fibrillation; atrial flutter; ventricular tachycardia; wolff-parkinson-white syndrome and belongs to the drug class group I antiarrhythmics. Risk cannot be ruled out during pregnancy. Propafenone 425 mg is not a controlled substance under the Controlled Substance Act (CSA).

Propafenone hydrochloride extended-release

Imprint:

WPI 2287

Strength:

425 mg

Color:

White

Shape:

Capsule-shape

Availability:

Prescription only

Drug Class:

Group I antiarrhythmics

Pregnancy Category:

C - Risk cannot be ruled out

CSA Schedule:

Not a controlled drug

Manufacturer:

Actavis Pharma, Inc.

More info Print Imprint Search

Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date, and complete, but no guarantee is made to that effect. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Copyright 2016 Drugs.com, National Library of Medicine, Truven Health Analytics and Cerner Multum, Inc. All Rights Reserved.